VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reached another development milestone in its oncology pipeline. The company announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development. This milestone reflects continued progress across the company’s therapeutic portfolio as it simultaneously expands the intellectual property supporting its next generation of antibody-based cancer therapies.
The announcement marks the successful completion of the discovery portion of VERAXA’s collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). OmniAb delivered a portfolio of therapeutic antibody binders, and VERAXA will now focus on building the final therapeutic candidate by combining these binders with its own proprietary antibody engineering, linker, and conjugation technologies. Although VXA-222 is not based on VERAXA’s BiTAC platform, it leverages these core technologies and represents one of the company’s more advanced development programs.
In parallel, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047. This robust IP estate underpins VERAXA’s commitment to building a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.
The advancement of VXA-222 and the expansion of its patent portfolio are significant steps for VERAXA as it seeks to establish itself in the competitive field of cancer therapeutics. By leveraging its proprietary technologies and strategic collaborations, the company aims to develop next-generation treatments that could offer improved efficacy and safety profiles for patients with challenging malignancies.
